Código QR (código de barras bidimensional)

Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide

In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendritic cell (DC) immunotherapy associated to standard radiochemotherapy with temozolomide (TMZ) followed by adjuvant TMZ. Three intradermal injections of mature DC loaded with autologous GBM ly...

ver descrição completa

Na minha lista:
Principais autores: Serena Pellegatta, Marica Eoli, Valeria Cuccarini, Elena Anghileri, Bianca Pollo, Sara Pessina, Simona Frigerio, Maura Servida, Lucia Cuppini, Carlo Antozzi, Stefania Cuzzubbo, Cristina Corbetta, Rosina Paterra, Francesco Acerbi, Paolo Ferroli, Francesco DiMeco, Laura Fariselli, Eugenio A. Parati, Maria Grazia Bruzzone, Gaetano Finocchiaro
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis Group 2018-04-01
coleção:OncoImmunology
Assuntos:
glioblastoma
dendritic cells
immunotherapy
adjuvant chemotherapy
natural killer cells
Acesso em linha:http://dx.doi.org/10.1080/2162402X.2017.1412901
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados